New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2012
08:40 EDTRHHBY, MAPP, RIGL, THLD, EXEL, TSPTLazard Capital to host a bus tour
Biotech Bus Tour travels throughout San Francisco to visit with various companies on April 2-4.
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
08:45 EDTRHHBYRoche has a conference call hosted by JPMorgan
Subscribe for More Information
November 30, 2015
15:53 EDTTHLDHigh option volume stocks
11:34 EDTTHLDOptions with increasing call volume; QUNR ASNA CIT THLD K ARO MON BURL SWN
Subscribe for More Information
10:05 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
November 25, 2015
09:35 EDTEXELExelixis announces European Commission approval of COTELLIC
Subscribe for More Information
November 23, 2015
08:19 EDTEXELExelixis shares look fairly valued, says Leerink
Subscribe for More Information
November 22, 2015
15:14 EDTEXEL, RHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 18, 2015
08:28 EDTRHHBY, EXELLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTRHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:01 EDTTHLDThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
November 17, 2015
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use